Key Points
Rahul Shah, VP-Equity Advisory, MOFSL, says post Covid, the numbers were not so great in the last year, year-and-a-half but in the last two quarters, back-to-back there has been a surge in the numbers and good numbers have come up across the board, not only in the largecap, but also in the midcap space..
Cannot take our eyes away from what is happening within the power sector..
Coming back to PFC and REC, there was strong commentary from both the management post the numbers and secondly still they are trading at good valuations and cheap valuations...
There could be some more upside with a dividend yield of 8% to 8.5%, with the dividend payout policy of 30% and way that come back in the power as a sector which is coming back, so this entire sector will get rerated and still there is a lot of room for them, PFC and REC especially..
If we start from, say, maybe a Sun with superb numbers both domestic as well as global and secondly, the speciality chemical division has also done very well.. Secondly, if we come back to plays like say Gland Pharma, which in the last three-four quarters were very volatile and post that and last quarters numbers which came up, Q1 quarter numbers were robust and we saw the price momentum..
